Clinical Focus ›› 2016, Vol. 31 ›› Issue (2): 218-220.doi: 10.3969/j.issn.1004-583X.2016.02.021

Previous Articles     Next Articles

Distribution and antimicrobial resistance surveillance of Pseudomonas aeruginosa isolates

Wei Hongliana, Yang Jingb, Yuan Yina, Liu Yuehonga, Shi Dongyana   

  1. a.Department of Laboratory; b.Hebei Provincial Center for Clinical Laboratory, the Second Hospital of Hebei Medical University, Shijiazhuang 050000,China
  • Received:2015-11-30 Online:2016-02-05 Published:2016-04-18
  • Contact: Shi Dongyan,Email:shidongyan73@126.com

Abstract: Objective To investigate the distribution and antimicrobial resistance of Pseudomonas aeruginosa isolated from clinical specimens and to make an effective control measure for carbapenem resistant P.aeruginosa.Methods Bacteria identification and drug sensitivity analysis were detected by VITEK 2 compact system (French bioMerieux), the result interpretation was according to the standard of CLSI 2014, and data were analyzed using WHONE5.6 software. Carbapenemases were determined using Carba NP test.Results There were 893 strains of P. aeruginosa isolated from all kinds of clinical samples in our hospital in 2014. Among them, mainly from the lower respiratory tract specimens (81.5%).The drug resistance of P. aeruginosa to Amikacin was the lowest (11.6%), followed by Piperacillin tazobactam and Levofloxacin, respectively 21.8% and 21.9%, the highest was Aztreonam (40.4%).Conclusion P. aeruginosa isolates were mainly form respiratory tract sputum specimens, Carbapenem resistant isolates were mainly from Department of respiratory medicine, ICU and Neurosurgery. Carbapenemases was mainly the Ambler class B metallo-β-lactamases (MBLs) of the VIM type. The use of antimicrobial agents should be reasonable in clinic and the monitoring of P. aeruginosa nosocomial infection should be strengthened.

Key words: pseudomonas aeruginosa, drug resistance, cross infection

CLC Number: